Where Should Enzalutamide Be in The Metastatic Castration Resistant Prostate Cancer (mCRPC): A Multi-center Study

Basit Öğe Kaydı
dc.contributor.authorKoca, Sinan
dc.contributor.authorOkten, Ilker Nihat
dc.contributor.authorBesiroglu, Mehmet
dc.contributor.authorTelli, Tugba Akin
dc.contributor.authorDemirci, Ayse
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorKucukarda, Ahmet
dc.date.accessioned2024-02-23T14:31:38Z
dc.date.available2024-02-23T14:31:38Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractObjectives: Enzalutamide(ENZ) is an effective hormonal treatment modality in mCRPC. It can be used before or after docetaxel(DTX) in this setting. Herein, we aimed to show the efficacy of ENZ before or after DTX use and the factors predicting the efficacy.Methods: We retrospectively collected the data of 320 patients from 12 centers who were treated with ENZ in mCRPC. The initial stage, age, line of treatment, serum prostate-specific antigen (PSA) levels before ENZ treatment and at nadir, site of metastasis, gleason score were evaluated.Results: Median age of 320 patients were 69. At a median follow-up of 56 months, 271/320 (84.7%) disease progression and 230/320(71.9%) death had been observed. Median PFS was 11(8.9-13)) and median OS was 25(22.1-27.8) months in all patients group. Median PFS was 10(7.4-12.5) months, 11(8-13.9) months in pre-DT X and post-DT X groups respectively. Median OS was higher in the post-DT X group than the pre-DT X group (28(25.7-30.2) vs 19(15.0-22.9-46.6) (p:0.000). Gleason score >= 8 (HR 0.59, 95%CI 0.46-0.77, p=0.00), presence of non-visceral metastasis (HR 0.72, 95%CI 0.53-0.97, p=0.031), initial PSA value<43(median) (HR 0.70, 95%CI 0.54-0.91, p=0.009), PSA at nadir <2 (HR 0.61, 95%CI 0.44-0.85, p=0.004), >50% decline in PSA (HR 0.27, 95%CI 0.19-0.36, p=0.000) significantly predicted ENZ response regarding rPFS.Conclusion: ENZ has shown equal efficacy before and after DTX treatment in mCRPC regarding rPFS. But OS rate was significantly better in the pre-DT X group. Therefore, we recommend starting with DTX in patients who can tolerate chemotherapy in mCRPC setting.en_US
dc.identifier.doi10.14744/ejmo.2023.69719
dc.identifier.endpage41en_US
dc.identifier.issn2587-196X
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85150276763en_US
dc.identifier.startpage34en_US
dc.identifier.urihttps://doi.org/10.14744/ejmo.2023.69719
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15275
dc.identifier.volume7en_US
dc.identifier.wosWOS:001135809500007en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofEurasian Journal Of Medicine And Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectProstate Canceren_US
dc.subjectEnzalutamideen_US
dc.subjectDocetaxelen_US
dc.subjectLine Of Treatmenten_US
dc.titleWhere Should Enzalutamide Be in The Metastatic Castration Resistant Prostate Cancer (mCRPC): A Multi-center Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu